Updates include interim results from the APG808 Phase 1 trial, data up to 12 months from the APG777 Phase 1 trial, details around the Company's strategy for combinations in AD, asthma and COPD to deliver better efficacy and dosing regimens, and the expected significant commercial potential of its programs.
Data up to 12 months reinforce APG777's best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing.
